ClinicalTrials.gg
CompletedNCT01581593Updated Feb 16, 2021Results posted

Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)

A Phase 3 interventional study of Kedrion IVIG 10% in Primary Immunodeficiency, Agammaglobulinemia and Hypogammaglobulinemia, sponsored by Kedrion S.p.A.. Completed at 15 sites in 2 countries. Open to participants aged 2 Years to 70 Years. Per ClinicalTrials.gov, last updated 2021-02-16.

Sponsored by Kedrion S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
45
Allocation
Not applicable
Ages
2 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
13th of 26
45 · median 45
Started
2012
the only one that year
Phase 3
18 of 27
2 open now
Registered
17th of 27
by date
Lead sponsor
3 of 27
Kedrion S.p.A.

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 13th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2012, is one of 18 in phase 3, and was the 17th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Kedrion IVIG 10% (an immunoglobulin solution) is effective in treating Primary Immunodeficiency (PID).

Read the detailed description

People with primary immunodeficiency diseases (PID) have a defective immune system and experience recurrent protozoal, bacterial, fungal and viral infections. Antibody deficiencies make up the largest group of PIDs.

The standard care for patients with PID is replacement immunoglobulin (a class of antibodies) solution. Prophylactic treatment with intravenous immunoglobulin (IVIG) solution has been shown to increase the time free from serious infection.

Kedrion IVIG 10% is a new preparation of an immunoglobulin G (IgG) solution. Kedrion IVIG 10% will be given by IV infusion to all study participants. The data collected will help determine whether Kedrion IVIG 10% is suitable for treating PID subjects.

03

Conditions studied

  • Primary Immunodeficiency
  • Agammaglobulinemia
  • Hypogammaglobulinemia
  • Antibody Deficiency

Keywords

  • Primary Immunodeficiency
  • PID
  • Agammaglobulinemia
  • Hypogammaglobulinemia
  • Antibody deficiency
04

Who can participate

Ages eligible
2 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Confirmed clinical diagnosis of a Primary Immunodeficiency Disease
  • Male or female, ages 2 to 70 years
  • Received 300-900 mg/kg of a licensed IVIG therapy at 21 or 28 day intervals for at least 3 months prior to this study
  • 2 documented IgG trough levels of ≥ 5 g/L are obtained at two infusion cycles (21 or 28 days) within 12 months (one must be within 6 months) prior to study enrolment
  • Non-pregnant females of who agree to use adequate during the study
  • Subject is willing to comply with the protocol
  • Authorization to access personal health information.
  • Signed the form and a child assent form, if appropriate.
  • If currently participating in a clinical trial with another experimental IVIG may be enrolled if they have received stable IVIG therapy for at least 3 infusion cycles prior to receiving Kedrion IVIG 10% and all inclusion and exclusion criteria are satisfied
  • If currently participating in a trial of SCIG can be enrolled if they are switched to IVIG for three infusion cycles (21 or 28 days) prior to enrolment in this study

Exclusion criteria

Exclusion Criteria:

  • Has secondary immunodeficiency.
  • Newly diagnosed and has not been treated with immunoglobulin or has been diagnosed with dysgammaglobulinemia or isolated IgG subclass deficiency.
  • Has a history of repeated reactions or to IVIG or other injectable forms of IgG.
  • Has a history of thrombotic events defined by at least 1 event in subject's lifetime.
  • Has IgA deficiency and is known to have antibodies to IgA.
  • Has received blood products other than human albumin or human immunoglobulin within 12 months prior to enrolment.
  • Has significant protein losing enteropathy, nephrotic syndrome or lymphangiectasia.
  • Has an acute infection as documented by culture or diagnostic imaging and/or a body temperature exceeding 38.5 °C (101.3 °F) within 7 days prior to screening
  • Has a known history or is positive at enrolment for (HIV) type 1 by NAT, virus (HBsAg and NAT), virus (by NAT), or hepatitis A virus (by NAT).
  • Has levels of (ALT) or aspartate aminotransferase (AST) > 2.5 times of the for the laboratory designated for the study.
  • Has an implanted venous access device
  • Has profound anemia or persistent severe neutropenia (≤ 1000 neutrophils per mm3)or lymphopenia of less than 500 cells per microliter.
  • Has a severe chronic condition such as renal failure (creatinine concentration > 2.0 times the upper limit of normal) with proteinuria, congestive heart failure ( III/IV), cardiomyopathy, cardiac arrhythmia associated with thromboembolic events (e.g. atrial fibrillation), unstable or advanced ischemic heart disease, hyperviscosity, or any other condition that the investigator believes is likely to interfere with evaluation of the study drug or with satisfactory conduct of the trial.
  • Has a history of a malignant disease other than properly treated carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin within 24 months prior to enrolment.
  • Has history of epilepsy or multiple episodes of migraine (defined as at least one episode within 6 months of enrolment) not completely controlled by medication.
  • Is receiving (oral or parenteral daily dose of ≥ 0.15 mg/kg/day of prednisone or equivalent) OR other drugs or chemotherapy.
  • Females who are pregnant, breast feeding or planning a pregnancy during the course of the study. Women who become pregnant during the study will be withdrawn from the study.
  • Has participated in another clinical study within 3 weeks prior to study enrolment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Kedrion IVIG 10%

    Kedrion IVIG 10% treatment.

    Biological: Kedrion IVIG 10%

Interventions

  • Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Treatment duration - 12 months

06

What researchers measure

Primary outcomes

  1. Incidence of Acute, Serious Bacterial Infections in the Total ITT Population.

    The incidence of acute serious bacterial infections, e.g. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis, meeting EMA and FDA criteria.

    Time frame: 13 months

Secondary outcomes

  1. Infections Other Than Acute, Serious Bacterial Infections (ASBIs) in the Total ITT Population.

    Time frame: 13 months

  2. Days Out of Work/School/Daycare Due to Infection in the Total ITT Population.

    Time frame: 13 months

  3. Days Unable to Perform Normal Daily Activities Due to Infection in the Total ITT Population.

    Time frame: 13 months

  4. Days on Therapeutic Antibiotics in the Total ITT Population.

    Time frame: 13 months

  5. Days of Unscheduled Visits to Physicians in the Total ITT Population.

    Time frame: 13 months

  6. Number of Hospitalizations Due to Infection in ITT Population.

    Time frame: 13 months

  7. Days of Hospitalization Due to Infection in the Total ITT Population.

    Time frame: 13 months

  8. Yearly Hospitalization Rate Due to Infection in the Total ITT Population.

    Time frame: 13 months

  9. Yearly Hospitalization Duration Due to Infection in the Total ITT Population.

    Time frame: 13 months

  10. Distribution of All-cause Hospitalizations in the Total ITT Population.

    Time frame: 13 months

  11. Duration of All-cause Hospitalizations

    Time frame: 13 months

  12. Distribution of Fever Episodes in the Total ITT Population.

    Time frame: 13 months

  13. Duration of Fever Episodes

    Time frame: 13 months

  14. IgG Trough Levels at Steady State in the Total ITT Population.

    Time frame: 13 months

07

Results

Posted Feb 16, 2021

Participant flow

Participant flow — Overall Study
MilestoneKedrion IVIG 10% 21 and 28 Days Infusion Schedule
Started45
Completed44
Not completed1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryIncidence of Acute, Serious Bacterial Infections in the Total ITT Population.

The incidence of acute serious bacterial infections, e.g. bacterial pneumonia, bacteremia/sepsis, bacterial meningitis, visceral abscess, osteomyelitis/septic arthritis, meeting EMA and FDA criteria.

Time frame:
13 months
Reported as:
Number · ASBI's/person-year
Incidence of Acute, Serious Bacterial Infections in the Total ITT Population.
ASBI's/person-yearKedrion IVIG 10% 21 and 28 Days Infusion Schedule
Incidence of Acute, Serious Bacterial Infections in the Total ITT Population.0.04 (0.00 to 0.11)
SecondaryInfections Other Than Acute, Serious Bacterial Infections (ASBIs) in the Total ITT Population.
Time frame:
13 months
Reported as:
Number · infect./subject's study duration (years)
Infections Other Than Acute, Serious Bacterial Infections (ASBIs) in the Total ITT Population.
infect./subject's study duration (years)Kedrion IVIG 10% 21 and 28 Days Infusion Schedule
Upper respiratory tract infection0.42
Sinusitis0.48
Viral upper respiratory tract infection0.15
Bronchitis0.11
Nasopharyngitis0.11
Rhinitis0.11
Acute sinusitis0.15
Gastroenteritis viral0.09
Herpes zoster0.11
Urinary tract infection0.11
SecondaryDays Out of Work/School/Daycare Due to Infection in the Total ITT Population.
Time frame:
13 months
Reported as:
Mean · days
Days Out of Work/School/Daycare Due to Infection in the Total ITT Population.
daysKedrion IVIG 10% 21 & 28 Days Treatment Schedule
Days Out of Work/School/Daycare Due to Infection in the Total ITT Population.2.8 ± 6.56
SecondaryDays Unable to Perform Normal Daily Activities Due to Infection in the Total ITT Population.
Time frame:
13 months
Reported as:
Mean · days
Days Unable to Perform Normal Daily Activities Due to Infection in the Total ITT Population.
daysKedrion IVIG 10% 21 and 28 Days Infusion Schedule
Days Unable to Perform Normal Daily Activities Due to Infection in the Total ITT Population.3.4 ± 6.53
SecondaryDays on Therapeutic Antibiotics in the Total ITT Population.
Time frame:
13 months
Reported as:
Mean · days
Days on Therapeutic Antibiotics in the Total ITT Population.
daysKedrion IVIG 10% 21 and 28 Days Infusion Schedule
Days on Therapeutic Antibiotics in the Total ITT Population.23.3 ± 33.77
SecondaryDays of Unscheduled Visits to Physicians in the Total ITT Population.
Time frame:
13 months
Reported as:
Mean · days
Days of Unscheduled Visits to Physicians in the Total ITT Population.
daysKedrion IVIG 10% 21 and 28 Days Infusion Schedule
Days of Unscheduled Visits to Physicians in the Total ITT Population.0.9 ± 1.14
SecondaryNumber of Hospitalizations Due to Infection in ITT Population.
Time frame:
13 months
Reported as:
Count of participants · Participants
Number of Hospitalizations Due to Infection in ITT Population.
ParticipantsKedrion IVIG 10% 21 & 28 Days Treatment Schedule
0 hospitalizations42
1 hospitalization2
2 hospitalizations1
≥ 3 hospitalizations0
SecondaryDays of Hospitalization Due to Infection in the Total ITT Population.
Time frame:
13 months
Reported as:
Mean · days
Days of Hospitalization Due to Infection in the Total ITT Population.
daysKedrion IVIG 10% 21 & 28 Days Treatments Schedule
Days of Hospitalization Due to Infection in the Total ITT Population.0.6 ± 2.21
SecondaryYearly Hospitalization Rate Due to Infection in the Total ITT Population.
Time frame:
13 months
Reported as:
Mean · hospitalizations per year
Yearly Hospitalization Rate Due to Infection in the Total ITT Population.
hospitalizations per yearKedrion IVIG 10% 21 & 28 Days Treatments Schedule
Yearly Hospitalization Rate Due to Infection in the Total ITT Population.0.11 ± 0.436
SecondaryYearly Hospitalization Duration Due to Infection in the Total ITT Population.
Time frame:
13 months
Reported as:
Mean · days
Yearly Hospitalization Duration Due to Infection in the Total ITT Population.
daysKedrion IVIG 10% 21 & 28 Days Treatments Schedule
Yearly Hospitalization Duration Due to Infection in the Total ITT Population.0.55 ± 2.196
SecondaryDistribution of All-cause Hospitalizations in the Total ITT Population.
Time frame:
13 months
Reported as:
Count of participants · Participants
Distribution of All-cause Hospitalizations in the Total ITT Population.
ParticipantsKedrion IVIG 10% 21 and 28 Days Treatment Schedule
0 hospitalizations41
1 hospitalization1
2 hospitalizations2
3 hospitalizations1
≥ 4 hospitalizations0
SecondaryDuration of All-cause Hospitalizations
Time frame:
13 months
Reported as:
Mean · days
Duration of All-cause Hospitalizations
daysKedrion IVIG 10% 21 and 28 Days Treatment Schedule
Duration of All-cause Hospitalizations17.8 ± 12.07
SecondaryDistribution of Fever Episodes in the Total ITT Population.
Time frame:
13 months
Reported as:
Count of participants · Participants
Distribution of Fever Episodes in the Total ITT Population.
ParticipantsKedrion IVIG 10% 21 and 28 Days Treatment Schedule
0 fever episodes34
1 fever episode6
2 fever episodes2
3 fever episodes1
4 fever episodes1
5 fever episodes1
SecondaryDuration of Fever Episodes
Time frame:
13 months
Reported as:
Mean · days
Duration of Fever Episodes
daysKedrion IVIG 10% 21 and 28 Days Treatment Schedule
Duration of Fever Episodes6.5 ± 4.87
SecondaryIgG Trough Levels at Steady State in the Total ITT Population.
Time frame:
13 months
Reported as:
Mean · mg/dL
IgG Trough Levels at Steady State in the Total ITT Population.
mg/dLKedrion IVIG 10% 21 and 28 Days Treatment Schedule
IgG Trough Levels at Steady State in the Total ITT Population.888 ± 197

Adverse events

Collected over 13 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Kedrion IVIG 10%—4/45 (8.9%)44/45 (97.8%)
Most frequent serious events
Most frequent serious events
EventKedrion IVIG 10%
Bacterial pneumoniaInfections and infestations1/45
Herpes zosterInfections and infestations1/45
Infective exacerbation of bronchiectasisInfections and infestations1/45
Bipolar disorderPsychiatric disorders1/45
DiarrhoeaGastrointestinal disorders1/45
Humerus FractureInjury, poisoning and procedural complications1/45
PneumoniaInfections and infestations1/45
Most frequent other events
Showing 10 of 36
Most frequent other events
EventKedrion IVIG 10%
Upper Respiratory Tract InfectionInfections and infestations13/45
HeadacheNervous system disorders12/45
InvestigationsInvestigations12/45
SinusitisInfections and infestations11/45
PyrexiaGeneral disorders11/45
CoughRespiratory, thoracic and mediastinal disorders10/45
FatigueGeneral disorders8/45
DiarrhoeaGastrointestinal disorders8/45
Back PainMusculoskeletal and connective tissue disorders7/45
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders6/45

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Kedrion IVIG 10% 21 and 28 Day Infusion Schedule
<=18 years9
Between 18 and 65 years27
>=65 years9
Age, Continuous
Age, Continuous(years)Kedrion IVIG 10% 21 and 28 Day Infusion Schedule
Mean39.9 ± 20.7
Sex: Female, Male
Sex: Female, Male(Participants)Kedrion IVIG 10% 21 and 28 Day Infusion Schedule
Female13
Male32
08

Study locations

15 sites
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Allergy Associates of the Palm Beaches
    North Palm Beach, Florida 33408, United States
  • Family Allergy & Asthma Center, PC
    Atlanta, Georgia 30342, United States
  • Rush University
    Chicago, Illinois 60612, United States
  • University of Iowa Hospital and Clinics
    Iowa City, Iowa 52242, United States
  • Midwest Immunology Clinic
    Plymouth, Minnesota 55446, United States
  • AAIR Research Center
    Rochester, New York 14618, United States
  • Optimed Research, LTD
    Columbus, Ohio 43235, United States
  • Dallas Allergy Immunology Research
    Dallas, Texas 75230, United States
  • AARA Research Center
    Dallas, Texas 75231, United States
  • Virginia Commonwealth University Health Systems
    Richmond, Virginia 23298, United States
  • Marycliff Allergy Specialists
    Spokane, Washington 99204, United States
  • Gordon Sussman Clinical Research Inc.
    Toronto, Ontario M4V1R2, Canada
  • Pediatric & Adult Allergy & Clinical Immunology
    Toronto, Ontario M5G1E2, Canada
  • The Hospital for Sick Children
    Toronto, Ontario M5G1X8, Canada
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2012 to primary completion in Aug 2014, 21 months.

Results were first posted in Feb 2021, 6 years 5 months after primary completion.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2012
First posted
Apr 20, 2012
StartActual
Nov 12, 2012
Primary completionActual
Aug 27, 2014
CompletionActual
Aug 27, 2014
Results first posted
Feb 16, 2021
Last update
Feb 16, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 16, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01581593
Lead sponsor
Kedrion S.p.A.
Responsible party
Sponsor
First posted
Apr 20, 2012
Start date
Nov 12, 2012
Primary completion
Aug 27, 2014
Completion
Aug 27, 2014
Results posted
Feb 16, 2021
Last update
Feb 16, 2021

Study contacts

Mirella Calcinai, MD
study director · Kedrion SpA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion